{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+antiviral+therapy", "query": { "intervention": "Combination antiviral therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 221, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+antiviral+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T22:08:54.668Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01726517", "title": "Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2012-10", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01726517" }, { "nct_id": "NCT00000628", "title": "A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "L-697,661", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-07-30", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 5, "location_summary": "San Francisco, California • Denver, Colorado • Chicago, Illinois + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000628" }, { "nct_id": "NCT00000838", "title": "Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 256, "start_date": null, "completion_date": "1998-03", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000838" }, { "nct_id": "NCT07115368", "title": "Study of GS-1219 in Participants With HIV-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "GS-1219", "type": "DRUG" }, { "name": "BVY", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2025-08-11", "completion_date": "2025-10-02", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115368" }, { "nct_id": "NCT00002220", "title": "Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Levocarnitine", "type": "DRUG" }, { "name": "Adefovir dipivoxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 120, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 11, "location_summary": "Los Angeles, California • New Haven, Connecticut • Wilmington, Delaware + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002220" }, { "nct_id": "NCT00722332", "title": "Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis B", "Liver Transplantation" ], "interventions": [ { "name": "HepaGam B", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cangene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 9, "start_date": "2008-02", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2013-11-01", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 15, "location_summary": "Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722332" }, { "nct_id": "NCT00367887", "title": "A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Peg-Intron", "type": "DRUG" }, { "name": "REBETOL", "type": "DRUG" }, { "name": "HCV 796", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 246, "start_date": "2006-10", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 34, "location_summary": "Anaheim, California • La Jolla, California • Los Angeles, California + 26 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00367887" }, { "nct_id": "NCT00000753", "title": "A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Atevirdine mesylate", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Zalcitabine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 30, "start_date": null, "completion_date": "1995-02", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 6, "location_summary": "Los Angeles, California • Miami, Florida • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000753" }, { "nct_id": "NCT01973049", "title": "UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Asunaprevir", "type": "DRUG" }, { "name": "BMS-791325", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo matching Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2013-12", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 26, "location_summary": "La Jolla, California • San Diego, California • San Francisco, California + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01973049" }, { "nct_id": "NCT03093740", "title": "Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Failure Chronic", "Hepatitis C" ], "interventions": [ { "name": "Zepatier", "type": "DRUG" }, { "name": "Zepatier plus Sofosbuvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2018-10-01", "completion_date": "2021-01-31", "has_results": false, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-09-16T22:08:54.668Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03093740" } ] }